Sensus Healthcare, Inc. (SRTS) Stock

Understand Sensus Healthcare, Inc.: how it makes money

Sensus Healthcare makes and sells superficial radiation therapy devices, including the SRT-100 and SRT-100 Vision systems, and primarily earns revenue from selling SRT-100 Vision systems to healthcare providers, with additional potential revenue from service contracts.

The profit model depends on whether shipped SRT-100 Vision systems translate into ongoing service agreement revenue, reflected by high service agreement coverage (80% of systems, and 80% for systems off one year warranty), while service contract revenue currently shows as 0.0B.

Business quality (Weak): Recent results show very small reported revenue (0.0B, likely rounding), with 14 systems shipped. Gross margin was 29.2%, but operating margin was sharply negative (-128.4%), and service and aesthetics revenue were 0.0B in the same period.

Bull case

• Gross margin of 29.2% in the latest period: This suggests the company can produce gross profit on its device-related revenue, even though overall operating results are currently weak.
• Service agreement coverage of 80% of systems: A large share of installed systems appear eligible for ongoing service, which can support repeatable cash flows if service revenue scales.
• Device momentum indicators, 14 systems shipped (SRT): The company is continuing to place systems with customers, which is the starting point for potential future service utilization.

Bear case

• Operating margin of -128.4%: Costs and/or non-gross-profit items are overwhelming gross profit in the latest period, indicating limited operating leverage right now.
• Reported revenue was 0.0B (with service contract revenue at 0.0B and aesthetics revenue at 0.0B): This limits visibility into whether recurring revenue is currently contributing to results.
• Large-customer concentration signals, 10 superficial radiation therapy system units shipped to a large customer: Meaningfully relying on a small number of customers can increase quarter-to-quarter volatility.
• Purchased systems as a percentage of systems shipped was 70%: A higher reliance on purchased systems can pressure control over costs, timing, and supply.

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

• DarioHealth Corp. (DRIO)
• Spectral AI, Inc. (MDAI)
• Nephros, Inc. (NEPH)
• Xtant Medical Holdings, Inc. (XTNT)
• PAVmed Inc. (PAVM)
• SANUWAVE Health, Inc. (SNWV)
• Accuray Incorporated (ARAY)
• Plus Therapeutics, Inc. (PSTV)